))
Expanded analysis of their data from their first clinical trial of troriluzole in SCA patients.
Manage episode 310696178 series 3068946
内容由Dana Mauro提供。所有播客内容（包括剧集、图形和播客描述）均由 Dana Mauro 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
This Podcast from the annual NAF Meeting in Las Vegas, March, 2019 features Gil L’Italien, PhD, Head of GHEOR and Epidemiology and Melissa Wolfe Beiner, MD, Director of Research and Development and Ataxia Medical Lead, both from Biohaven Pharmaceuticals. They are with us to highlight some important and encouraging new data from an expanded analysis of their data from their first clinical trial of troriluzole in SCA patients. This clinical trial was the first registrational trial in SCA patients in the United States. In addition, they will discuss a new clinical trial, which is beginning this month at sites across the country, studying troriluzole in SCA patients with a new study design, optimized from data from their initial study, as well as data from the US Natural History Study. This work reflects a collaboration between Biohaven and numerous experts in the ataxia field across the country.
55集单集
分享
